IFC awards pioneering research in the diagnosis of Multiple Sclerosis at the “IDEA² Global Awards” of MIT
Within the framework of the 2nd edition of the “IDEA2 Global Awards” given by the prestigious Massachusetts Institute of Technology (MIT), the “Industrial Farmacéutica Cantabria Award” was presented to the research team of the Hospital Regional Universitario de Málaga and its iSOL project, pioneering work in the diagnosis of Multiple Sclerosis. Pilar Matji, on behalf of the Spanish laboratory Industrial Farmacéutica Cantabria (IFC), presented the award for this work for “its great potential in changing the people’s lives”.
The awarded Project involves the clinical implementation of a tool to detect a serum biomarker that helps in the diagnosis of Multiple Sclerosis and proposes the use a recombinant protein (rh-iSOL) as potential treatment for this disease. The work was presented by Begoña Oliver Martos as principal investigatory of the team from this Malaga hospital, and by Óscar Fernández, Laura Leyva Fernández, Mª Jesús Pinto Medel as Patricia Urbaneja Romero as collaborating investigators.
In August 2017, Industrial Farmacéutica Cantabria and MIT signed the agreement that establishes that the Spanish laboratory sponsor and promotes, until 2020, Biomedical Innovation programmes and activities of the prestigious Massachusetts Institute of Technology. Not in vain, the philosophy of MIT- which since it was founded has promoted and considered scientific research as the most powerful tool in the grasp of humanity to improve the quality of life of people and make the world a better place-, fully coincides with the mission and values of Industrial Farmacéutica Cantabria.
IFC joins the “IDEA² Global” programme of MIT, whose objective is to support the most innovative biomedical technologies and its sponsors to convert its research in products and services that have a real impact on healthcare.